News
SHJBF
2.060
NaN%
--
Weekly Report: what happened at SHJBF last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at SHJBF last week (0415-0419)?
Weekly Report · 04/22 12:32
Weekly Report: what happened at SHJBF last week (0408-0412)?
Weekly Report · 04/15 12:22
Weekly Report: what happened at SHJBF last week (0401-0405)?
Weekly Report · 04/08 12:28
Weekly Report: what happened at SHJBF last week (0325-0329)?
Weekly Report · 04/01 12:24
Shanghai Junshi Biosciences reports FY results
Seeking Alpha · 03/29 12:53
Weekly Report: what happened at SHJBF last week (0318-0322)?
Weekly Report · 03/25 12:28
Weekly Report: what happened at SHJBF last week (0311-0315)?
Weekly Report · 03/18 12:26
Weekly Report: what happened at SHJBF last week (0304-0308)?
Weekly Report · 03/11 12:20
BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Seeking Alpha · 03/08 10:10
Weekly Report: what happened at SHJBF last week (0226-0301)?
Weekly Report · 03/04 12:25
Weekly Report: what happened at SHJBF last week (0219-0223)?
Weekly Report · 02/26 12:46
Weekly Report: what happened at SHJBF last week (0212-0216)?
Weekly Report · 02/19 12:48
Weekly Report: what happened at SHJBF last week (0205-0209)?
Weekly Report · 02/12 12:32
Weekly Report: what happened at SHJBF last week (0129-0202)?
Weekly Report · 02/05 12:45
Weekly Report: what happened at SHJBF last week (0122-0126)?
Weekly Report · 01/29 12:26
Junshi Hopes New Scientist CEO Can Cure Its Woes
Seeking Alpha · 01/25 08:58
Weekly Report: what happened at SHJBF last week (0115-0119)?
Weekly Report · 01/22 12:33
Weekly Report: what happened at SHJBF last week (0108-0112)?
Weekly Report · 01/15 12:27
Coherus ends Junshi-partnered TIGIT Program in portfolio shakeup
Coherus BioSciences ends Junshi-partnered TIGIT Program in portfolio shakeup. The U.S. Biotech preannounced its 2023 results, indicating $255M – $260M in net revenue for the year. Coherus and Junshi Biosciences will end their collaboration on a group of cancer drugs called anti-TIGIT antibodies.
Seeking Alpha · 01/10 12:24
More
Webull provides a variety of real-time SHJBF stock news. You can receive the latest news about Shanghai Junshi through multiple platforms. This information may help you make smarter investment decisions.
About SHJBF
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.